Sign in
Taking peopleNo phase

Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia

Key facts

Who runs it
Nantes University Hospital
Where
France5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
300 people, planned
Started
2 Jan 2025
Expected to end
1 Jan 2029
Type of study
Interventional, 4 groups
Treatments tested
  • Blood samples
  • Oropharyngeal swabs
  • ECG
  • Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration
Record updated
4 June 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Group A (patients with acute cardiac disease)
  • Male or female
  • Hospitalized for acute coronary syndrome for less than 7 days
  • Informed consent from the patient
  • Person insured under a health insurance scheme; Group B (patients with chronic cardiovascular disease)
  • Male or female,
  • Undergoing coronary artery by-pass surgery
  • Hospitalized in intensive care unit for \> 12 hours
  • Informed consent from the patient
  • Person insured under a health insurance scheme; Group C (patients at risk of CVRD without chronic cardiovascular disease)
  • Male or female,
  • Familial high levels of cholesterol or triglycerides
  • With no personal history of CVRD, with a recent negative cardiac exercise test (last test inferior to 12 months)
  • Follow-up for lipid abnormalities at high risk of CVRD events
  • Informed consent from the patient
  • Person insured under a health insurance scheme; Group D (patients with HAP)
  • Male or female
  • With one or more risk factors for CVD among:; Age ≥ 65 years old Smoking, Abnormal lipidic levels, High blood pressure, Obesity, Diabetes mellitus, Chronic kidney disease
  • Cured from mechanically ventilated HAP during the current hospitalization
  • Informed consent from the patient or relatives
  • Person insured under a health insurance scheme

Who cannot take part

  • Immunosuppression pre-existing to the index hospitalisation, defined as lymphopenia; 500 elements/mm3, haematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug
  • Age <80 years old
  • Groups A, B, C and D
  • Pregnant women, breastfeeding women
  • Adults under guardianship or trusteeship
  • Low probability of survival at day 28; o Groups A, B, C
  • Community-acquired pneumonia or Hospital-acquired pneumonia within the last year

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The "HOMI-LUNG" project is an international, interdisciplinary project that aims to better understand the causal links between respiratory tract infections (i.e. pneumonia) and the progression of cardiovascular disease. More specifically, the project aims to quantify the burden of cardiovascular disease after pneumonia and assess patients; acceptability of long-term health alterations, as well as to define pneumonia endotypes with distinct pathobiological mechanisms associated with exacerbation of cardiovascular disease.

The 4 groups in the trial

  • Group A : Patients with acute major cardiovascular eventOther group

    Comparator

    Treatment: Blood samples, Oropharyngeal swabs, ECG, and Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration

  • Group B: Patients with severe chronic cardiovascular diseaseOther group

    Comparator

    Treatment: Blood samples, Oropharyngeal swabs, ECG, and Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration

  • Group C: Patients with a high risk of CVD, yet no known history of CVRD or HAOther group

    Comparator

    Treatment: Blood samples, Oropharyngeal swabs, and ECG

  • Group D: Patients cured of HAPTreatment being tested

    Treatment: Blood samples, Oropharyngeal swabs, ECG, and Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia - the HOMI-LUNG Project - Hospital-Acquired-Pneumonia
Criteria questions
Built from NCT06602934, who can take part
Record updated
4 June 2026